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Abstract: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and 
corticobasal degeneration (CBD) are the most common atypical parkinsonisms. These disorders 
are characterized by varying combinations of autonomic, cerebellar and pyramidal system, and 
cognitive dysfunctions. In this paper, we reviewed the evidence available on the presence and 
type of neuropsychiatric disturbances in MSA, PSP, and CBD. A MedLine, Excerpta Medica, 
PsycLit, PsycInfo, and Index Medicus search was performed to identify all articles published on 
this topic between 1965 and 2018. Neuropsychiatric disturbances including depression, anxiety, 
agitation, and behavioral abnormalities have been frequently described in these disorders, with 
depression as the most frequent disturbance. MSA patients show a higher frequency of depressive 
disorders when compared to healthy controls. An increased frequency of anxiety disorders has 
also been reported in some patients, and no studies have investigated apathy. PSP patients may 
have depression, apathy, disinhibition, and to a lesser extent, anxiety and agitation. In CBD, 
neuropsychiatric disorders are similar to those present in PSP. Hallucinations and delusions are 
rarely reported in these disorders. Neuropsychiatric symptoms in MSA, PSP, and CBD do not 
appear to be related to the severity of motor dysfunction and are one of the main factors that 
determine a low quality of life. The results suggest that neuropsychiatric disturbances should 
always be assessed in patients with atypical parkinsonisms.
Keywords: atypical parkinsonisms, multiple system atrophy, progressive supranuclear palsy, 
corticobasal degeneration, neuropsychiatric disturbances, depression
Introduction
Atypical parkinsonisms (APs) are neurological conditions which differ from 
Parkinson’s disease (PD) mainly because of the wider involvement of the central ner-
vous system.1 APs include multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), and corticobasal degeneration (CBD). These are relatively rare disorders 
characterized by progressive parkinsonism, a poor response to levodopa treatment, 
and clinical signs due to the involvement of the autonomic, cerebellar, and pyramidal 
systems.2 Cognitive dysfunctions are also present in these disorders. Patients affected 
by APs often complain of neuropsychiatric disturbances.3 It is however unclear whether 
each type of AP displays specific neuropsychiatric disorders or whether psychiatric 
disorders are part of the disease spectrum or are secondary to the severity of motor 
impairment. It is also unclear whether neuropsychiatric symptoms may be present in 
the early phase of the disease and how they impact the quality of life of these patients. 
To answer these questions, we reviewed the evidence available on neuropsychiatric 
disorders in patients with MSA, PSP, and CBD. For the purposes of the paper, we first 
summarized the most important clinical features of each clinical condition.
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Methods
A systematic review of neuropsychiatric disturbances 
in MSA, PSP, and CBD was performed using MedLine, 
Excerpta Medica, PsycLit, PsycInfo, and Index Medicus 
search to identify all papers published on this topic between 
1965 and 2018. The PRISMA statement for reporting sys-
tematic reviews was followed.4 The search terms used were: 
MSA OR PSP OR CBD OR CBS OR anxiety OR depression 
OR obsessive compulsive disorders OR hallucinations OR 
delusions OR psychosis OR delirium OR disinhibition OR 
abnormal behaviour OR disinhibition. We first reviewed 
the titles and abstracts and applied the selection criteria 
outlined previously with the exception of study design 
(Figure 1). Only articles published in English, peer-reviewed 
journals were considered and full articles were examined 
to consider their relevance based on the inclusion criteria. 
Possible discrepancies between the reviewers with regard 
to the inclusion criteria were resolved through consultation 
with the senior author (GF). In addition, reference lists of 
the papers were also examined. We excluded meta-analyses 
and systematic reviews, and studies which did not clearly 
report statistical analysis, diagnostic criteria, or the number 
of patients included. The principal reviewer (DB) checked 
all items. Then, three reviewers independently inspected all 
citations of the studies identified by the search and grouped 
them according to topic.
A quality assessment was performed as shown in 
Tables 1–3. Studies were rated for quality assessment using 
the following criteria: 1) pathological confirmation of the 
diagnosis: no confirmation: 0 points; confirmation: 2 points; 
2) presence of a control group: no control group: 0 points; 
control group (either other disease or healthy controls [HC]): 
1 point; both HC + other disease: 2 points; 3) number of 
subjects assessed: 0 points if N20; 1 point if N between 20 
Figure 1 Flowchart of the search and selection process.
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Table 1 Summary of studies on neuropsychiatric disturbances in MSA
Reference Sample Study design Aim Methods Main results Quality score
Pilo et al, 19969 12 MSA, 12 PD Observational, 
cross-sectional
Motor disability and 
mood disorders in 
MSA and PD
interview for major 
depression, BDi
Moderate depressive 
symptoms in 3 MSA. 
No major depression 
detected
i =0
ii =1
iii =1
iv =1
v =1
vi =1
Total score =4
Gill et al, 199910 15 Shy Drager 
syndrome
Observational, 
cross-sectional
Frequency 
and severity 
of depressive 
symptoms
BDi (mailed 
questionnaires)
Depressive symptoms 
in 13 patients, mild in 9, 
moderate-severe in 4
i =0
ii =0
iii =0
iv =0
v =1
vi =1
Total score =2
Fetoni et al, 199911 12 MSA, 12 PD Observational, 
cross-sectional
Psychiatric 
disturbances in 
MSA and PD
BDi, HAMD, BPRS MSA: 1 dysthymia, 
1 major depression
i =0
ii =1
iii =1
iv =0
v =1
vi =1
Total score =4
Benrud-Larsen et al, 
200512
99 MSA Patients identified 
from computerized 
database; 
observational
Depressive 
symptoms in 
relation to life 
satisfaction
BDi (mailed 
questionnaire)
Mild depressive 
symptoms in 40 patients, 
moderate in 30, severe 
in 7
i =0
ii =0
iii =2
iv =0
v =1
vi =1
Total score =4
Schrag et al, 200613 115 MSA 
(comparison of 
data with PD 
from literature)
Multicenter, 
observational, 
cross-sectional
Determinant of 
quality of life in 
MSA
BDi, SF36, 
Compass, and 
others
Moderate-severe 
depression in 53 patients. 
Depression associated 
with poor HR-QoL.
Mean BDi score higher in 
MSA than in PD (similar 
disease duration)
i =0
ii =0
iii =2
iv =0
v =1
vi =1
Total score =4
Kawai et al, 200817 21 MSA-C, 14 
MSA-P, 21 HC
Observational, 
case–control
Cognitive 
dysfunction in 
MSA-C vs MSA-P
HADS Higher level of 
depression both in 
MSA-C and MSA-P 
compared to HC, but no 
differences between the 
two subtypes
i =0
ii =2
iii =1
iv =0
v =1
vi =1
Total score =5
Schrag et al, 201014 188 PSP, 286 
MSA
Multicenter 
observational, 
case–control
To compare 
depression, anxiety, 
and health status in
PSP and MSA
HADS, eQ-5D 55.6% of PSP and 
43% of MSA probable 
depression. 37.3% of PSP 
and 37.3% of MSA had 
probable anxiety
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Balas et al, 201018 25 MSA, 12 
PD, 10 HC
Observational, 
cross-sectional
Cognitive 
dysfunction and 
mood in MSA-C vs 
MSA-P vs HC
Self-evaluation 
state anxiety, trait 
anxiety, depression
MSA-P and PD higher 
level of depression 
than HC. MSA-C 
increased level of anxiety 
compared to HC
i =0
ii =2
iii =1
iv =0
v =1
vi =0
Total score =4
(Continued)
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Table 1 (Continued)
Reference Sample Study design Aim Methods Main results Quality score
winter et al, 201115 46 MSA, 
40 PSP
Observational, 
case–control
Factors determining 
quality of life in PSP 
and MSA
BDi, eQ-5D Depression independent 
predictor of low quality 
of life
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Siri et al, 201316 61 MSA, 20 PD Multicenter, 
observational, 
cross-sectional
Cognitive and 
behavioral features 
in MSA-P and 
MSA-C compared 
to PD
NPi, GDS Depression in 62% of 
MSA, 10% of PD. NPi 
scores similar between 
MSA and PD; GDS and 
NPi scores similar in 
MSA-C and MSA-P
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Kawahara et al, 
201519
33 MSA, 
14 cortical 
cerebellar 
atrophy, 
106 HC
Cross-sectional Cognitive and 
affective functions 
in MSA-C, MSA-P, 
and cortical 
cerebellar atrophy
GDS GDS scores higher in 
MSA-P, MSA-C, cortical 
cerebellar atrophy than 
HC. No differences 
between the three 
disorders
i =0
ii =2
iii =2
iv =0
v =1
vi =1
Total score =6
Cao et al, 201520 110 MSA, 
55 HC
Cross-sectional Frontal lobe 
function and 
behavioral changes 
in MSA patients
FBi, FAB, MMSe, 
others
22.7% of MSA patients 
had mild frontal lobe 
dysfunction, 57% 
moderate, 2.7% severe
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Abbreviations: MSA, multiple system atrophy; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; BDi, Beck Depression inventory; HAMD, Hamilton Rating 
Scale Depression; BPRS, brief psychiatric rating scale; SF36, Short Form (36) Health Survey; MSA-C, multiple system atrophy cerebellar type; MSA-P, multiple system atrophy 
parkinsonian type; HC, healthy controls; HADS, Hospital Anxiety and Depression Scale; eQ-5D, euroQol-5-dimensions; NPi, Neuropsychiatric inventory; GDS, Geriatric 
Depression Scale; FBi, Frontal Behavior inventory; FAB, Frontal Assessment Battery; MMSe, Mini Mental State examination; HR-QoL, health-related quality of life.
Table 2 Summary of studies on neuropsychiatric disturbances in PSP
Reference Sample Study design Aim Methods Main results Quality score
Menza et al, 
199534
19 PSP, 42 PD Observational Psychiatric 
symptoms in PSP 
and PD
DSM-iii, Zung 
Depression Scale; 
GDS; Zung Self-
Rated Anxiety Scale
Major depression 
in 2, dysthymia in 1, 
adjustment disorders 
in 5. No differences 
between PSP and PD in 
depression and anxiety 
measures
i =0
ii =1
iii =1
iv =0
v =1
vi =2
Total score 6
Maher and Lees, 
198625
52 PSP Observational Clinical features and 
natural history
Descriptive At diagnosis: personality 
changes in 12 patients, 
depression in 8, 
emotional lability in 9
i =0
ii =0
iii =2
iv =0
v =1
vi =0
Total score 3
esmonde et al, 
199633
25 PSP, 25 HC Observational, 
case–control
Motor, cognitive, 
and psychiatric 
disturbances in PSP 
and HC
BDi BDi =11–17, n=7, BDi 
18–23, n=3, BDi =24 
n=3. No correlation 
between BDi scores, 
disease severity, and 
neuropsychological 
parameters
i =0
ii =1
iii =1
iv =0
v =1
vi =1
Total score =4
(Continued)
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Table 2 (Continued)
Reference Sample Study design Aim Methods Main results Quality score
Litvan et al, 
199627
22 PSP, 20 AD, 
40 HC
Observational, 
case–control
Behavioral symptoms 
in PSP, AD, and HC
NPi Apathy in 91%, 
disinhibition in 36%, 
dysphoria and anxiety in 
18%, irritability, abnormal 
motor behaviors, or 
agitation 9%
i =0
ii =2
iii =2
iv =0
v =1
vi =1
Total score =6
Litvan et al, 
199828
34 PSP, 15 CBD, 
25 HC
Observational, 
case–control
Behavioral features 
in PSP, CBD, and HC
NPi Apathy more frequent in 
PSP patients. Depression 
and irritability more 
frequent in CBD
i =0
ii =2
iii =2
iv =0
v =1
vi =1
Total score =6
Aarsland et al, 
200129
61 PSP/144 PD Observational, 
case–control
Psychiatric 
symptoms in PSP 
and PD. Correlation 
of neuropsychiatric 
symptoms with 
clinical variables
NPi Total NPi score higher in 
PSP than in PD. Higher 
apathy and disinhibition 
scores in PSP compared 
to PD
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Nath et al, 
200326
187 PSP Clinical cohort 
study
Clinical features 
and natural history 
of PSP
No specific rating 
scales used
At onset personality 
change in 8 patients, 
depression, anxiety, and 
apathy in 5. During the 
disease, apathy present in 
50% of the patients
i =0
ii =0
iii =2
iv =1
v =1
vi =0
Total score =4
Josephs and 
Dickson, 200342
137 PSP, 43 
clinically diagnosed 
as PSP but non-
PSP at pathological 
diagnosis
Clinicopathological 
correlation
Description of 
clinical features 
differentiating PSP 
from non-PSP
Descriptive case 
histories
Psychosis in 18% of 
true PSP and in 44% of 
non-PSP
i =2
ii =1
iii =2
iv =1
v =1
vi =0
Total score =7
Papapetropulos 
and Mash, 200543
22 PSP Clinicopathological 
correlation
Assessment of visual 
hallucinations
Descriptive case 
histories
visual hallucinations in 
2/22 patients
i =2
ii =0
iii =2
iv =1
v =1
vi =0
Total score =6
Borroni et al, 
200841
24 PSP, 39 PD, 
27 LBD, 16 CBS
Observational, 
case–control
Frequency, type 
of behavioral 
disturbances in the 
mild stages of PSP, 
PD, LBD, CBS
NPi PSP: depression in 50%, 
anxiety in 40%, sleep 
disturbances and eating 
abnormalities in 30%, 
apathy in 22%
i =0
ii =1
iii =2
iv =1
v =1
vi =1
Total score =6
Borroni et al, 
200931
57 PSP/68 CBS Observational, 
case–control
Behavioral 
abnormalities in PSP 
and CBS
FBi FBi scores low in both 
groups. Apathy more 
frequent in PSP
i =0
ii =1
iii =2
iv =1
v =1
vi =1
Total score =6
(Continued)
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Table 2 (Continued)
Reference Sample Study design Aim Methods Main results Quality score
Schrag et al, 
201014
188 PSP, 286 MSA Multicenter 
observational
To compare 
depression, anxiety, 
and health status in
PSP and MSA
HADS, eQ-5D 55.6% of PSP and 
43% of MSA probable 
depression. 37.3% of PSP 
and 37.3% of MSA had 
probable anxiety
i =0
ii =1
iii =2
iv =0
v =1
vi =1
Total score =5
Yatabe et al, 
201137
10 PSP, 13 FTD Observational, 
cross-sectional
Compare 
neuropsychiatric 
symptoms, 
stereotypical, and 
antisocial behaviors 
in PSP and FTD
NPi; Stereotypy 
Rating inventory
NPi comparable 
between PSP and FTD. 
High scores for apathy, 
aberrant motor behavior, 
disinhibition, and low 
scores for stereotypical 
behavior in PSP
i =0
ii =1
iii =0
iv =0
v =1
vi =1
Total score =3
winter et al, 
201115
40 PSP, 46 MSA Observational Factors determining 
quality of life in PSP 
and MSA
BDi, eQ-5D Depression independent 
predictor of low quality 
of life
i =0
ii =1
iii =1
iv =0
v =1
vi =1
Total score =4
Gerstenecker 
et al, 201330
154 PSP Multicenter, 
observational
Type and clinical 
correlates of 
neuropsychiatric 
profile in PSP
NPi Apathy in 62%, 
depression in 58%, 
anxiety in 24%, sleep 
abnormalities in 52%, 
eating disorders in 39.6%, 
aggression/agitation in 
35.6%
i =0
ii =0
iii =2
iv =0
v =1
vi =1
Total score =4
Bloise et al, 
201435
28 PSP, 28 HC Case–control 
observational 
study
Frequency of 
psychiatric disorders 
differs in patients 
with PSP and 
age-matched healthy 
controls
DSM-iv criteria 
with structured 
interview HAM-D, 
HAM-A, BPRS
Psychiatric disturbances 
in 15 PSP and in 5 HC. 
8 PSP patients with 
depressive disorders due 
to PSP
i =0
ii =1
iii =1
iv =0
v =1
vi =2
Total score =5
Abbreviations: PSP, progressive supranuclear palsy; PD, Parkinson’s disease; MSA, multiple system atrophy; LBD, Lewy body dementia; HC, healthy controls; AD, Alzheimer’s 
disease; CBD, corticobasal degeneration; CBS, corticobasal syndrome; FTD, frontotemporal dementia; BDi, Beck Depression inventory; NPi, Neuropsychiatric inventory; 
HADS, Hospital Anxiety and Depression Scale; eQ-5D, euroQol-5-dimensions; FBi, Frontal Behavior inventory; GDS, Geriatric Depression Scale; BPRS, brief psychiatric rating 
scale; DSM-iii, Diagnostic and Statistical Manual for Mental disorders, 3rd edition; HAM-D, Hamilton Rating Scale for Depression; HAM-A, Hamilton Rating Scale for Anxiety.
and 100; 2 points if 100; 4) follow-up assessment: no 
follow-up: 0 points; follow-up: 1 point; 5) data presentation: 
unclear data presentation: 0 points; clear data presentation: 
1 point; and 6) type of psychiatric assessment: no rating 
scales used: 0 points; use of rating scales for psychiatric 
symptoms: 1 point; diagnosis according to DSM criteria 
with structured interview and rating scales for psychiatric 
symptoms: 2 points.
MSA
MSA is a rare, sporadic progressive neurodegenerative 
disease. It is clinically characterized by a combination of 
parkinsonism, cerebellar dysfunction, pyramidal signs, and 
autonomic failure.5,6 MSA is classified in two variants on the 
basis of prominent clinical features: the parkinsonian type 
(MSA-P) and the cerebellar type (MSA-C).6,7 Pathologically, 
MSA is characterized by the accumulation of glial cytoplas-
mic inclusions of alpha-synuclein in the oligodendrocytes of 
several cortical and sub-cortical regions.8
Neuropsychiatric symptoms in MSA
Pilo et al (1996)9 reported findings of 12 patients with 
MSA and 12 patients with PD (but not HC) using the Beck 
Depression Inventory (BDI) and a non-structured interview 
to assess the features of major depressive disorders. None 
of the patients interviewed had a major depressive disorder, 
and only three MSA patients and three PD patients had 
BDI scores over 18. Using a BDI mailed questionnaire, 
Gill et al (1999)10 reported depressive symptoms in 13 of 
the 15 patients with Shy Drager syndrome (a form of MSA 
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Table 3 Summary of studies on neuropsychiatric disturbances in CBD
Reference Sample Study design Aim Methods Main results Quality score
Mimura  
et al, 
199747
3 CBD Case reports Clinical characteristics 
of CBD
Profile of mood 
status
2 patients with 
depressed mood
i =0
ii =0
iii =0
iv =1
v =1
vi =0
Total score =2
Massman  
et al, 
199648
21 CBD, 21 AD Observational, 
case–control
Neuropsychological 
functions in CBD and AD
GDS CBD patients show 
more depressive 
symptoms than 
AD patients
i =0
ii =1
iii =1
iv =0
v =1
vi =1
Total score =4
Litvan et al, 
199828
34 PSP, 15 CBD, 
25 HC
Observational, 
case–control
Compare behavioral 
features of CBD, PSP, 
and HC
NPi Apathy more frequent 
in PSP patients. 
Depression and 
irritability more 
frequent in CBD
i =0
ii =2
iii =2
iv =0
v =1
vi =1
Total score =6
wenning  
et al, 
199849
14 CBD Clinicopathological 
correlation
Natural history of 
14 CBD patients with
Post-mortem 
confirmation
Descriptive case 
histories
Apathy, irritability, 
disinhibition at disease 
onset in 3 patients and 
in 7 at last visit
i =2
ii =0
iii =0
iv =1
v =1
vi =0
Total score =4
Moretti  
et al, 
200552
10 CBD Observational, with 
18 months follow-up
Neuropsychiatric 
disturbances with respect 
to asymmetric motor 
symptoms presentation
BeHAve-AD 
delusions, 
hallucinations, 
aggressiveness, 
sleep disturbances, 
affective disorders, 
anxiety, and phobias
Patients with left-sided 
symptoms: more 
disinhibition, apathy, 
irritability; patients 
with predominantly 
right-sided symptoms: 
more depression
i =0
ii =0
iii =0
iv =1
v =1
vi =1
Total score =3
Geda et al, 
200750
36 CBD Clinicopathological 
correlation
Neuropsychiatric features 
in 36 CBD patients 
with post-mortem 
confirmation
Descriptive case 
histories
Neuropsychiatric 
disturbances in  
8 patients. Type of 
neuropsychiatric 
symptoms depending 
on clinical phenotype
i =2
ii =0
iii =1
iv =1
v =1
vi =0
Total score =5
Borroni  
et al, 
200841
24 PSP, 39 PD, 
27 LBD, 16 CBS
Observational Frequency and type of 
behavioral disturbances 
in the mild stages of PSP, 
PD, LBD, CBS
NPi Depression in 50%, 
anxiety in 40%, sleep 
disturbances and 
eating abnormalities in 
30%, apathy in 22%
i =0
ii =1
iii =2
iv =1
v =1
vi =1
Total score =6
Borroni  
et al, 
200931
57 PSP/68 CBS Observational Behavioral abnormalities 
in PSP and CBS
FBi FBi scores low in both 
groups. Apathy more 
frequent in PSP
i =0
ii =1
iii =1
iv =0
v =1
vi =2
Total score =5
Abbreviations: CBD, corticobasal degeneration; AD, Alzheimer’s disease; PSP, progressive supranuclear palsy; HC, healthy controls; PD, Parkinson’s disease; LBD, Lewy 
body dementia; CBS, corticobasal syndrome; GDS, Geriatric Depression Scale; BeHAve-AD, Behavioral Pathology in AD Rating Scale; NPi, Neuropsychiatric inventory; 
FBi, Frontal Behavior inventory.
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characterized by predominant autonomic dysfunction) in 
an uncontrolled study. Depressive symptoms were rated as 
mild in nine patients and moderate to severe in four and did 
not correlate with disability. Fetoni et al (1999)11 compared 
12 patients with PD and 12 with possible MSA-P (with 
similar disability scores) using the Hamilton Rating Scale 
for Depression (HAM-D), supported by the DSM-IV criteria 
for depression, and the brief psychiatric rating scale (BPRS). 
No HC were assessed in this study. The authors found that 
only two of the MSA patients had a BDI score indicative of 
depression (one had a score of 10 and one a score of 18). The 
remaining ten patients had a score 7. When compared with 
PD patients, patients with MSA had higher scores on items 
indicating “blunted affect”, which suggests that MSA patients 
are emotionally indifferent to their condition.11
In comparison to the previously mentioned studies, which 
report findings from small numbers of patients, other authors 
assessed larger populations of MSA patients. Benrud-Larson 
et al (2005),12 using a computerized database of patients seen 
at the Mayo Clinic between 1998 and 2002, found that 40 of 
the 99 MSA patients they analyzed had BDI scores consis-
tent with mild depression, 30 with moderate depression, and 
seven with severe depression. The authors did not compare 
the data with a control population. More than one third of 
the patients in their study were taking antidepressant medi-
cations. Similar findings emerged from a large, multicenter, 
multinational survey of the European MSA-Study Group 
conducted on 115 MSA patients, which detected moderate 
or severe depression, defined on the basis of a BDI score 
of 17 points or higher, in approximately half of the MSA 
patients studied.13 When the results obtained from MSA 
patients were compared with those of PD patients collected 
from the literature, Schrag et al concluded that there were 
no differences between the BDI scores of MSA and PD 
patients. Schrag et al (2010)14 used the Hospital Anxiety and 
Depression Scale (HADS) in a multicenter study to compare 
psychiatric disturbances in 286 MSA patients and 188 PSP 
patients. No HC were included in this study. The authors 
found that 43% of the MSA patients had probable depres-
sion and 37.3% had probable anxiety. Depressive symptoms 
measured with the BDI, appeared to be an independent 
predictor of quality of life in a study that compared 46 MSA 
patients with 40 PSP patients.15 In a recent multicenter study 
on 61 MSA patients and 20 PD patients used as controls, 
Siri et al (2013)16 found that the mean total Neuropsychiatric 
Inventory (NPI) value in MSA patients was not statistically 
different from that in PD patients (16.2±15.7 and 21.9±14.8, 
respectively), but that mild to severe depression, as assessed 
by the Geriatric Depression Scale (GDS), was present in 62% 
of MSA patients and in only 10% of PD patients.
Data on whether neuropsychiatric symptoms are more fre-
quent in one of the two variants of MSA (MSA-P and MSA-C) 
are controversial. Kawai et al (2008),17 in a study in which 
the primary endpoint was to assess the degree of cognitive 
impairment, investigated 21 patients with MSA-C, 14 patients 
with MSA-P, and 21 age- and education-matched HC. Using 
the HADS, the authors found that patients with MSA-P and 
MSA-C had comparably higher levels of depression (8.7±3.8 
and 9.1±3.8, respectively) than HC (4.6±2.7). Balas et al 
(2010)18 compared cognitive deficits and mood disorders in 
15 patients with MSA-P, ten with MSA-C, 12 with PD, and 
ten HC. In this study, the presence of neuropsychiatric distur-
bances was evaluated by means of patient self-administered 
questionnaires (state anxiety, trait anxiety, depression). When 
compared with HC, MSA-P patients displayed abnormally 
increased levels of depression and anxiety, whereas MSA-C 
patients only displayed an increased level of anxiety. More 
recently, Kawahara et al (2015)19 examined cognition, affec-
tive ability, and vitality in 25 patients with MSA-C, eight 
with MSA-P, and 14 with cortical cerebellar atrophy. Both 
MSA-C and MSA-P patients had higher GDS scores than 
patients with cortical cerebellar atrophy. Cao et al (2015)20 
investigated frontal cognitive and behavioral deficits using the 
Frontal Assessment Battery and Frontal Behavioral Inventory 
(FBI) in 110 Chinese patients with MSA (43 with MSA-P and 
67 with MSA-C) and 55 HC. They found that 41.6% of the 
patients had a frontal lobe dysfunction, characterized mainly 
by deficits in inhibitory control. Logophenic aphasia was pres-
ent in 60.9% of the sample and apathy in 43.6%. Higher FBI 
scores were associated with increased severity of disease, as 
assessed by the Unified Multiple System Rating Scale.
Patients with MSA only rarely manifest visual hallucina-
tions, being reported in approximately 5% of cases compared 
to up of 75% of PD patients. Therefore, despite not excluding 
a diagnosis of MSA, visual hallucinations should at least raise 
suspicions of a different diagnosis.21
Table 1 provides a summary of studies assessing neurop-
sychiatric disturbances in MSA.
PSP
PSP is a rare neurological disorder characterized by usually 
symmetrical parkinsonism, supranuclear gaze palsy, axial 
rigidity, gait disturbances, postural instability with early falls, 
and fronto-limbic cognitive dysfunction.22 Clinicopathologi-
cal studies have revealed that several clinical and pathological 
variants of PSP exist.23,24 Pathologically, PSP is characterized 
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Neuropsychiatric disturbances in atypical parkinsonian disorders
by abnormal hyperphosphorylated tau accumulation in sev-
eral areas of the brain.22
Neuropsychiatric dysfunction 
in PSP
Neuropsychiatric alterations have been described in PSP 
patients even in the early phases of the disease. Neuro-
behavioral abnormalities (personality changes, depressive 
symptoms, emotional lability) were already present at diag-
nosis in 31 out of 52 PSP patients in a study on the natural 
history of the disease.25 In another clinical cohort enrolled in 
a natural history study, Nath et al (2003)26 described person-
ality changes, irritability, anhedonia, and depressed mood 
upon presentation in 15% of the 187 PSP patients studied. 
Neuropsychiatric disturbances at disease onset, as assessed 
by means of the NPI, were also found in two of the 22 PSP 
patients studied by Litvan et al (1996).27 More specific neu-
ropsychiatric disturbances emerge in PSP patients during 
the disease course. The NPI detected apathy in 20 of the 
22 patients studied by Litvan et al (1996).27 In their study, the 
apathy score in PSP patients was higher than that observed 
in 40 HC and 50 patients with Alzheimer’s disease (AD). 
Moreover, apathy was detected in 80% of the patients at 
some time during the course of the disease and was rated in 
most cases as moderate to severe. In a subsequent study on 34 
PSP patients, Litvan et al (1998)28 confirmed, by means of the 
NPI, that apathy was the most frequently reported psychiatric 
symptom and that it was significantly more frequent in PSP 
patients than in 15 CBD patients and 25 HC. Similarly, 93 of 
the 187 PSP patients studied by Nath et al (2003)26 displayed 
apathy, although no formal rating scale was used in their 
study. When Aarsland et al (2001)29 compared the NPI scores 
in 61 PSP patients and 144 PD patients (though not in HC), 
they found that apathy and disinhibition scores were higher 
in PSP patients than in PD patients, whereas hallucination 
and delusion scores were higher in PD than in PSP patients.29 
The NPI was also used in a more recent multicenter study on 
a sample of 154 PSP patients.30 The authors of that study con-
firmed that apathy, which was present in 62% of the sample, 
was the most frequent behavioral symptom in PSP; however, 
depressive symptoms, which were reported in 58% of the 
patients, also emerged as a significant feature. No relationship 
was detected either between apathy and depression scores or 
between neuropsychiatric disturbances and age, age at onset, 
education, disease duration, and severity of motor impairment 
(as measured by means of the Progressive Supranuclear Palsy 
Rating Scale). Using the FBI in 68 PSP and 57 CBD patients, 
Borroni et al (2009)31 found apathy in more than half of the 
PSP patients and in approximately one third of the CBD 
patients. Apathy in their study did not correlate with the 
severity of motor impairment as assessed by the UPDRS. In 
another study based on the Cambridge Behavioral Inventory, 
which is a caregiver-based questionnaire, the apathy scores 
assigned by caregivers were high in 35% of PSP patients 
despite low scores in the mood subtest.32
Other studies have demonstrated that depressive symp-
toms are the most frequent neuropsychiatric abnormality in 
PSP patients. Esmonde et al (1996)33 diagnosed depression, as 
measured by means of the BDI, in 13 of the 25 PSP patients 
they studied. Depressive symptoms were mild in seven 
patients, moderate in three, and severe in three (data on HC 
were not provided). Depression in their study did not correlate 
with other clinical or demographic parameters such as the 
severity of disease or cognitive impairment. When Schrag et 
al (2010)14 used the HADS to compare 188 PSP patients with 
286 MSA patients, they found that 55.6% of the PSP patients 
had probable depression. Interestingly, the HADS depression 
subscore in their study was the factor more significantly asso-
ciated with quality of life measures. Depression is a main find-
ing in PSP patients even when a more conservative psychiatric 
assessment, such as the structured psychiatric interview, is 
used. When Menza et al (1995)34 used the Diagnostic and 
Statistical Manual for Mental disorders, 3rd edition criteria, 
they found that two of the 19 PSP patients studied had major 
depression, one had dysthymia, and five were diagnosed 
with adjustment disorders. However, when these 19 PSP 
patients were compared with a sample of 42 PD patients, no 
differences emerged between the two patient groups in either 
the frequency or the severity of psychiatric disturbances. 
Bloise et al (2014)35 conducted a case–control study using 
the structured clinical interview for DSM-IV (SCID-I) on 28 
PSP patients and 28 age-matched HC. The authors found that 
psychiatric disturbances were significantly more frequent in 
PSP patients than in controls (53% vs 17.3%). It is noteworthy 
that eight patients were diagnosed as having mood disorders 
due to PSP.35 Supporting the hypothesis that depression may 
be part of the clinical spectrum of PSP, is the observation that 
no differences in the clinical demographic variables emerged 
between PSP patients with and those without depressive dis-
orders or symptoms either in the study by Bloise et al (2014)35 
or in the study by Gertstenecker et al (2013).30 Depression in 
PSP patients may be severe enough to lead, albeit very rarely, 
to a completed suicide.36
Anxiety, agitation, and irritability are also observed 
in PSP patients, though to a lesser extent than apathy and 
depression. Indeed, only three of the 19 PSP patients studied 
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by Menza et al (1995)34 had anxiety disorders. This finding 
was confirmed by the fact that anxiety did not emerge as a 
major determinant of health status in the 188 PSP patients 
studied by Schrag et al (2010)14 by means of the HADS 
and that the presence of anxiety explained only 5% of the 
variance relative to health status. When Gerstenecker et al 
(2013)30 used the NPI, they found that significant anxiety 
was present in 24% of the PSP patients, agitation in 36%, 
irritability in 33%, and disinhibition in 32%. By contrast, no 
PSP patient was diagnosed as having an anxiety disorder in 
the case–control study by Bloise et al (2014),35 which sug-
gests that the use of a structured clinical interview yields the 
most conservative results.
PSP patients also display neuropsychiatric symptoms 
that reflect frontal lobe dysfunction, such as emotional 
blunting, disinterest and disinhibition behaviors, stereotyp-
ies, rituals, and greedy eating habits. Disinhibition may be 
present in up to one third of PSP patients according to some 
studies.27,29 At least one antisocial behavior (physical assault, 
hypersexuality, neglect of the traffic rules, and public urina-
tion) was reported in five out of ten PSP patients in another 
study.37 By contrast, Borroni et al (2009)31 did not describe 
typical disinhibition behaviors in any of their PSP patients. 
In the only study that assessed the presence of obsessive 
compulsive personality disorders in PSP, Nicoletti et al 
(2016)38 compared 14 PSP patients with 15 MSA patients, 
16 essential tremor patients, and 20 HC. Obsessive compul-
sive personality disorders were observed in five (35.7%) PSP 
patients, two (13.3%) MSA patients, two (12.5%) essential 
tremor patients, and two (10%) controls. PSP patients may 
also display disordered social interactions, such as problems 
in interacting and communicating with family members. 
Changes in emotion processing, which may be studied by 
using tests that assess facial expression recognition, may, at 
least in part, be responsible for these problems. Indeed, facial 
expression recognition for all negative emotions was found 
to be impaired in PSP patients,39 and recognition of sad and 
happy emotional faces was found to be impaired to a greater 
extent in PSP patients than in PD patients matched for age, 
disease duration, cognition, and depression.40
Hallucinations and delusions are rarely observed in PSP. 
None of the 24 PSP patients with a mean disease duration 
of approximately 3 years studied by Borroni et al (2008)41 
displayed delusions or hallucinations. When pathologically 
confirmed cases of PSP were compared with clinically mis-
diagnosed PSP cases with other pathologies,42 psychosis was 
found to be the only behavioral abnormality that was less 
frequent in the pathologically confirmed PSP cases (18% vs 
41%, P0.01). Papapetropolous and Mash (2005)43 reported 
that only two of the 22 pathologically confirmed PSP patients 
displayed visual hallucinations during the disease course. 
Similar data emerged from a large, retrospective multicenter 
study based on a pathologically confirmed diagnosis, in 
which only ten of the 100 PSP patients had visual hallucina-
tions during the disease course.44 When hallucinations are 
present, their characteristics are similar to those observed 
in PD.43
Table 2 provides a summary of studies assessing neurop-
sychiatric disturbances in PSP.
CBD
CBD is a rare, progressive neurodegenerative disorder 
with variable clinical presentation. Corticobasal syndrome 
(CBS), the most frequent clinical presentation of pathologi-
cally confirmed CBD, is characterized by an akinetic-rigid 
parkinsonian syndrome with a poor response to levodopa 
and a combination of asymmetric motor (rigidity, akinesia, 
dystonia, and myoclonus) and non-motor (apraxia, agnosia, 
cortical sensory loss, and alien limb phenomena) symp-
toms, which may be associated with cognitive-behavioral 
disorders.45,46 Other clinical presentations are possible. CBD 
is characterized by neuronal tau pathology that mainly affects 
the forebrain.45,46
Neuropsychiatric symptoms in CBD
When Mimura et al (1997)47 described the clinical features 
of three CBD patients, they found that two had a depressed 
mood (Table 3). In a study designed to compare the neu-
ropsychological functions in 21 CBD patients and 21 AD 
patients, depressive symptoms were found to be more severe 
in CBD than in AD (GDS score 14.2 and 5.2, respectively).48 
The GDS score in CBD patients correlated with disease 
duration.48 Litvan et al (1998)28 were the first to systemati-
cally investigate the frequency and type of neuropsychiat-
ric disturbances in patients with CBD. By using the NPI, 
the authors found that depression was present in 73% of 
patients, apathy in 40%, irritability in 20%, and agitation in 
20%. When they compared the NPI scores of CBD patients, 
PSP patients, and HC, the authors of that study found that 
depression was more frequent in CBD and that apathy was 
more frequent in PSP. Wenning et al (1998)49 clinically fol-
lowed 14 CBD patients whose diagnosis was later confirmed 
at the post-mortem examination. The authors found that 
apathy, irritability, and disinhibition were present at disease 
onset in three patients and were observed in a further four 
patients at the last visit. A more recent study on a cohort of 
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
10
0.
74
.8
9 
on
 1
5-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2653
Neuropsychiatric disturbances in atypical parkinsonian disorders
36 neuropathologically confirmed CBD patients documented 
the presence of neuropsychiatric disturbances in 22% of 
the patients.50 The authors classified the patients in three 
subtypes according to their predominant clinical phenotype: 
1) progressive aphasia/frontotemporal dementia (FTD); 2) 
FTD; and 3) CBS. These three groups displayed different 
neuropsychiatric traits: patients with an aphasia/FTD pheno-
type displayed compulsive behaviors, socially inappropriate 
and disinhibited behavior, and a voracious appetite, patients 
with an FTD phenotype displayed irritability, aggressivity, 
and impaired judgement, while those with a CBS phenotype 
mainly displayed depression. Borroni et al (2008)41 com-
pared the presence and type of behavioral disturbances in 
CBD, PD, Lewy body dementia (LBD), and PSP patients. 
The NPI scores were indicative of depressive symptoms in 
50% of the CBD patients. In a subsequent study, Borroni et 
al (2009)31 reported frontal lobe dysfunction symptoms in 
CBD patients whose score was similar to that observed in 
PSP patients. An analysis of the FBI subscores in their study 
revealed that spontaneity and language were impaired in CBD 
patients, but that they did not display disinhibition. Moretti 
et al (2005)52 investigated whether CBD patients with clearly 
asymmetric symptoms differ in terms of neuropsychiatric 
disturbances. When they used the Behavioral Pathology in 
AD rating scale to specifically measure seven items from the 
scale (delusions, hallucinations, activity disorders, aggres-
siveness, sleep disturbances, affective disorders, and anxiety 
and phobias), the authors observed that patients with left-
sided symptoms displayed a greater degree of disinhibition, 
apathy and irritability, and a lower degree of depression than 
patients with predominantly right-sided symptoms.52 Lastly, 
visual hallucinations and delusions in CBD patients were not 
described either in the study by Litvan et al (1998)28 or in 
that by Geda et al (2007).50
Table 3 provides a summary of studies assessing neurop-
sychiatric disturbances in CBD.
Discussion
In the present paper, we reviewed the data from studies that 
assessed the frequency and type of neuropsychiatric distur-
bances in MSA, PSP, and CBD, which are the most frequent 
APs.51 The studies reviewed confirm that neuropsychiatric 
disturbances, a frequent finding in all three disorders: 1) are 
characterized by relatively heterogeneous clinical manifesta-
tions; 2) are not secondary to the severity of motor impair-
ment; 3) may be present even at disease onset, before motor 
symptoms become manifest; and 4) may be detrimental to 
the quality of life of both patients and their caregivers.
Early studies on neuropsychiatric symptoms in MSA have 
provided conflicting results, probably because of limitations 
in the number of patients studied and in the methodology 
used to assess psychiatric symptoms.9,10 When using validated 
questionnaires such as the BDI and the NPI, MSA patients 
display moderate to severe depressive symptoms and affec-
tive detachment,11–16 which have a marked impact on qual-
ity of life.13–15,54 A position paper by the Neuropsychology 
Task Force of the MDS-MSA study group confirmed that 
approximately 37% of patients with MSA may manifest 
depression.53 Studies that have compared MSA with PD failed 
to show clear differences between these two conditions.9–11 
Whether neuropsychiatric disturbances differ between the 
two variants of MSA (MSA-P and MSA-C) is unclear.16,17,19 
The presence of depression in MSA in all the studies we 
reviewed appears to be independent of the severity of motor 
impairment, thereby suggesting that depression is part of the 
clinical spectrum of the disease rather than secondary to the 
severity of motor dysfunction.
Studies that adopted the structured psychiatric interview 
in PSP have consistently demonstrated that depressive dis-
orders are more frequent in PSP patients than in controls, 
and are more frequent than anxiety disturbances.34,35 The 
observation that depression is due to PSP35 (according to the 
SCID) and that the severity of depressive symptoms does 
not correlate with the severity of motor impairment30,33,35 
suggest that depression is part of the clinical spectrum of 
the disease and not merely a reactive process. Depression 
may also be a major determinant of subjective health status 
in PSP patients,14,15 albeit to a lesser degree than symptoms 
related to frontal lobe dysfunction.54 When less conservative 
diagnostic instruments, such as questionnaires, were used to 
measure neuropsychiatric symptoms, apathy was shown to 
be the most frequent symptom in PSP patients.27–31 As the 
presence and severity of apathy and depression are not cor-
related in PSP,14,30 these two symptoms should be considered 
separately.
PSP patients also display symptoms related to frontal 
lobe dysfunction. Disinhibition, changes in eating habits 
(voracious appetite), and socially inappropriate behaviors 
may be observed, together with increased levels of anxiety 
and agitation.14,27,30,41 The presence of these symptoms, which 
sometimes occur early in the disease course, may complicate 
the differential diagnosis not only with degenerative disorders 
such as FTD but also with primary psychiatric conditions. 
One noteworthy observation is that delusions and halluci-
nations are very rarely observed in PSP patients.42,43 This 
observation is in contrast to the high rate of hallucinations 
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and delusions observed in synucleinopathies such as LBD, 
PD, and PD-dementia.21 The absence of visual hallucinations 
may thus serve as a useful diagnostic marker in uncertain 
cases that supports a diagnosis of PSP.
Owing to the variable clinical phenotypic presentation 
of CBD,55 studies on neuropsychiatric disturbances in this 
disorder are more difficult to interpret. If studies based on 
a pathologically confirmed diagnosis are considered,49,50 
neuropsychiatric disturbances in CBD patients are character-
ized above all by depression and apathy, whereas disinhibi-
tion and behavioral abnormalities are less frequent. Studies 
designed to compare CBD and PSP patients have shown that 
depression is more common in CBD patients while apathy is 
more common in PSP patients.28,29 As in PSP, hallucinations 
and delusions are very rarely reported in CBD patients.
MSA patients manifest a decreased activity in all major 
neurotransmitter systems.56–59 Most of the aforementioned 
studies detected correlations between changes in neu-
rotransmitter function and motor and vegetative symptoms, 
though it is unclear whether changes in neurotransmission 
also underlie neuropsychiatric symptoms in MSA. Other 
studies have shown that mood disturbances in MSA patients 
correlate with deficits in cognitive performances,18 thereby 
highlighting a possible pathophysiological link between 
frontal cognitive and behavioral/psychiatric disturbances in 
patients with MSA. These findings are in keeping with neu-
roimaging studies that have revealed frontal lobe dysfunction 
in patients with MSA.6
In PSP, apathy may result from auto-activation deficits 
and a lack of self-initiated behaviors, which may be due to the 
disconnection of the orbitofrontal cortex (OFC) and lateral 
prefrontal regions from the sub-cortical regions, including the 
pulvinar, dorsomedial and anterior nuclei of the thalamus, and 
superior and inferior culliculum.60 Depression in PSP may, at 
least in part, be due to the severe dopaminergic loss observed 
in this condition both in the striatum61 and in the extranigral 
A10 midbrain cell groups, which innervate the motor and 
limbic cortical and thalamic regions.62 Severe noradrenergic 
changes may be directly linked to cognitive and behavioral 
manifestations in PSP, such as rigidity and impulsivity.63 
Cholinergic abnormalities may also be involved in neurop-
sychiatric abnormalities in PSP.64–66
In CBD, Huey et al (2015)67 found that reduced gray mat-
ter volume in the right medial ventral prefrontal cortex (PFC) 
was associated with increased anxiety and apathy, reduced 
volume in the right lateral ventral PFC with apathy and inap-
propriate repetitive behaviors, and reduced volume in the 
left lateral ventral PFC with poor performance in executive 
function tests. The same authors found that degeneration 
of the right medial OFC correlated with increased anxiety 
and apathy in patients with CBS, whereas degeneration of 
the lateral OFC was related to a greater extent with apathy 
and inappropriate behaviors.67 Clinicopathological studies 
have also shown that neuronal loss in the subthalamic 
nucleus and substantia nigra in patients with pathologically 
confirmed CBD whose initial symptoms fell within the 
neurobehavioral domain was less severe than that observed 
in patients who displayed motor symptoms from disease 
onset.68 Recent neuroimaging69–71 and neurophysiological 
findings72 suggest that asymmetric brain changes in patients 
with CBD may underlie the pathophysiology of asymmetric 
clinical symptoms, including neuropsychiatric and behavioral 
abnormalities. Finally, the loss of dopaminergic activity may 
explain the high frequency of depressive disorders observed 
in CBD patients.59,73
The review we conducted highlighted a number of limi-
tations in the studies considered. First, few studies used a 
standardized psychiatric interview to diagnose psychiatric 
disorders. This is particularly true of the studies conducted 
on MSA, none of which assessed the presence of neuropsy-
chiatric disorders through a structured interview. Another 
limitation that emerged is that not all the studies examined 
compared the results obtained in MSA, PSP, and CBD 
with those of HC or patients with other neurodegenerative 
disorders. Due to the relatively rare conditions investigated, 
several studies we reviewed enrolled only a limited number 
of patients. Lastly, the clinical assessment of the patients was 
followed by a pathological confirmation of the diagnosis in 
few studies. It should also be underlined that the majority 
of papers we reviewed only investigated the presence of 
neuropsychiatric symptoms in the different APs. Only a 
limited number of papers, mainly case series or case reports, 
have reported the efficacy of drug treatment in psychiatric 
disturbances. Future studies should therefore be designed to 
evaluate the efficacy and safety of different interventions in 
neuropsychiatric disturbances in APs.
Conclusion
We found that depression is the most frequent neuropsychiatric 
disturbance in all three disorders examined. Further studies are 
needed to understand whether other neuropsychiatric symp-
toms, such as apathy, anxiety, and behavioral disturbances, 
markedly affect MSA patients. Besides manifesting depres-
sion, PSP patients also display a high frequency of apathy, 
disinhibition, personality changes, and eating disorders; anxi-
ety and irritability are two other symptoms that are relatively 
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
10
0.
74
.8
9 
on
 1
5-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2655
Neuropsychiatric disturbances in atypical parkinsonian disorders
common in PSP. The neuropsychiatric profile of CBD patients 
is similar to that observed in PSP patients, although studies 
in which these two populations were compared suggest that 
depression is more common in CBD while apathy is more 
common in PSP. Finally, as hallucinations, delusions, and 
psychoses are rarely observed in all these disorders, the pres-
ence of such symptoms should raise the suspicion of a different 
diagnosis. We conclude that as the evidence regarding the 
burden exerted by neuropsychiatric symptoms on the quality 
of life of patients, as well as of their caregivers, is unequivo-
cal, it should be assessed on a routine basis.
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